Eli Lilly will acquire Morphic Holding for $3.2 billion in cash, the companies said on Monday, giving the U.S. drugmaker access to an experimental drug for types of inflammatory bowel diseases.
Grifols said its board held an extraordinary meeting over the weekend to study a preliminary offer presented by Brookfield and the founding family, which has a nearly 30% stake.
Despite the evidence that early initiation of acute treatment results in better outcomes, many patients do not take their medication in a timely manner and significant patient education will be required to drive a shift in their administration habits.
The lipid-modifying agents market, which had seen a dramatic decline over the past decade, is now set for a spectacular revival, driven by the innovating therapies Leqvio (inclisiran) from Novartis and Repatha (evolocumab) from Amgen. These two treatments are forecast to spreadhead the market’s resurgence, bringing it back to prominence by 2030, according to GlobalData.
ReutersRoche will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda by Merck, casting further doubt on the drug candidate pioneered by the Swiss company.
Patients using Novo Nordisk’s wildly popular weight-loss drug Wegovy and its similar medicines for type 2 diabetes may be at increased risk for a sight-threatening eye condition, according to data from a study published on Wednesday.